203 related articles for article (PubMed ID: 2027989)
1. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.
Wahl RL; Cody RL; Hutchins GD; Mudgett EE
Radiology; 1991 Jun; 179(3):765-70. PubMed ID: 2027989
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
3. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma.
Gritters LS; Francis IR; Zasadny KR; Wahl RL
J Nucl Med; 1993 Sep; 34(9):1420-7. PubMed ID: 8355058
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy.
Chaiken L; Rege S; Hoh C; Choi Y; Jabour B; Juillard G; Hawkins R; Parker R
Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):455-64. PubMed ID: 8407422
[TBL] [Abstract][Full Text] [Related]
5. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.
Wahl RL; Zasadny K; Helvie M; Hutchins GD; Weber B; Cody R
J Clin Oncol; 1993 Nov; 11(11):2101-11. PubMed ID: 8229124
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.
Adler LP; Crowe JP; al-Kaisi NK; Sunshine JL
Radiology; 1993 Jun; 187(3):743-50. PubMed ID: 8497624
[TBL] [Abstract][Full Text] [Related]
7. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings.
Crowe JP; Adler LP; Shenk RR; Sunshine J
Ann Surg Oncol; 1994 Mar; 1(2):132-40. PubMed ID: 7834438
[TBL] [Abstract][Full Text] [Related]
9. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability.
Scheidhauer K; Scharl A; Pietrzyk U; Wagner R; Göhring UJ; Schomäcker K; Schicha H
Eur J Nucl Med; 1996 Jun; 23(6):618-23. PubMed ID: 8662094
[TBL] [Abstract][Full Text] [Related]
10. Positron-emission tomographic scanning of primary and metastatic breast carcinoma with the radiolabeled glucose analogue 2-deoxy-2-[18F]fluoro-D-glucose.
Wahl RL; Cody R; Hutchins G; Mudgett E
N Engl J Med; 1991 Jan; 324(3):200. PubMed ID: 1984203
[No Abstract] [Full Text] [Related]
11. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.
Bender H; Kirst J; Palmedo H; Schomburg A; Wagner U; Ruhlmann J; Biersack HJ
Anticancer Res; 1997; 17(3B):1687-92. PubMed ID: 9179219
[TBL] [Abstract][Full Text] [Related]
12. Lung tumor metastasis to breast detected by fluorine-18-fluorodeoxyglucose PET.
Hunter GJ; Choi NC; McLoud TC; Fischman AJ
J Nucl Med; 1993 Sep; 34(9):1571-3. PubMed ID: 8394885
[TBL] [Abstract][Full Text] [Related]
13. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.
Hoh CK; Hawkins RA; Glaspy JA; Dahlbom M; Tse NY; Hoffman EJ; Schiepers C; Choi Y; Rege S; Nitzsche E
J Comput Assist Tomogr; 1993; 17(4):582-9. PubMed ID: 8331230
[TBL] [Abstract][Full Text] [Related]
14. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma.
Port ER; Yeung H; Gonen M; Liberman L; Caravelli J; Borgen P; Larson S
Ann Surg Oncol; 2006 May; 13(5):677-84. PubMed ID: 16538409
[TBL] [Abstract][Full Text] [Related]
15. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography: 2-deoxy-2-[18F]-fluoro-D-glucose uptake in locally advanced breast cancers.
Bruce DM; Evans NT; Heys SD; Needham G; BenYounes H; Mikecz P; Smith FW; Sharp F; Eremin O
Eur J Surg Oncol; 1995 Jun; 21(3):280-3. PubMed ID: 7781797
[TBL] [Abstract][Full Text] [Related]
17. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose.
Shreve PD; Grossman HB; Gross MD; Wahl RL
Radiology; 1996 Jun; 199(3):751-6. PubMed ID: 8638000
[TBL] [Abstract][Full Text] [Related]
18. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]tyrosine PET.
Kole AC; Nieweg OE; Pruim J; Paans AM; Plukker JT; Hoekstra HJ; Schraffordt Koops H; Vaalburg W
J Nucl Med; 1997 May; 38(5):692-6. PubMed ID: 9170429
[TBL] [Abstract][Full Text] [Related]
19. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies.
Shulkin BL; Mitchell DS; Ungar DR; Prakash D; Dole MG; Castle VP; Hernandez RJ; Koeppe RA; Hutchinson RJ
Radiology; 1995 Feb; 194(2):495-500. PubMed ID: 7824731
[TBL] [Abstract][Full Text] [Related]
20. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.
Newman JS; Francis IR; Kaminski MS; Wahl RL
Radiology; 1994 Jan; 190(1):111-6. PubMed ID: 8259386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]